Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles
Diseases of the Esophagus · 2025-11-01 · 38 (6)
DOI: 10.1093/dote/doaf101 ↗Abstract
Abstract Esophageal squamous cell carcinoma is a major global health challenge in its locally advanced stages. Neoadjuvant chemoimmunotherapy aims to downstage tumors before surgery, but the optimal number of cycles remains uncertain. We performed a single-institution retrospective study of 208 consecutive patients with resectable, locally advanced esophageal squamous cell carcinoma treated between March 2020 and April 2024. Patients received either two (n = 84) or three (n = 124) cycles of platinum-based chemotherapy plus a programmed death-1 inhibitor, followed by esophagectomy without planned radiotherapy. Primary outcomes were pathologic complete response and disease-free survival; safety and clinical-to-pathologic downstaging were prespecified secondary end points. Three cycles yielded higher objective response (75.0% vs. 60.7%) and a higher pathologic complete response of the primary tumor (27.4% vs. 11.9%) than two cycles. Disease-free survival favored three cycles (hazard ratio, 0.52). Treatment-related adverse events occurred more often with three cycles, driven mainly by bone-marrow suppression (32.3% vs. 11.9%) but were generally manageable and compatible with timely surgery. Overall survival did not differ within the current median follow-up of 21 months. This retrospective analysis suggests that three cycles of neoadjuvant chemoimmunotherapy may provide greater tumor response and improved disease-free survival compared with two cycles in operable esophageal squamous cell carcinoma, with acceptable toxicity. However, neoadjuvant chemoradiation—which typically achieves higher pathologic complete response rates—remains the standard of care. Longer follow-up and prospective, stratified trials are needed to validate these findings and to define the role of a radiation-free strategy in appropriately selected patients.
EUVIMED